GeneDx WGS
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
GeneDx (WGS) Core Market Data and Business Metrics
Latest Closing Price
$84.87Price-Earnings Ratio
-43.75Total Outstanding Shares
28.07 Million SharesDividend
No dividendSIC Description
Services-health ServicesPrimary Exchange
NASDAQHeadquarters
333 Ludlow Street, Stamford, CT, 06902
Historical Stock Splits
If you bought 33 shares of WGS before May 4, 2023, you'd have 1 share today.
| Execution Date | Split Amount |
|---|---|
| May 4, 2023 | 1-for-33 (Reverse Split) |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 832,752 Shares | 2.99 | 3/14/2025 | 2,491,153 Shares |
| 1,617,649 Shares | 1.56 | 2/28/2025 | 2,524,962 Shares |
| 1,540,630 Shares | 1.79 | 2/14/2025 | 2,754,589 Shares |
| 657,160 Shares | 3.25 | 1/31/2025 | 2,139,029 Shares |
| 1,092,488 Shares | 1.96 | 1/15/2025 | 2,137,846 Shares |
| 506,588 Shares | 4.1 | 12/31/2024 | 2,079,064 Shares |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities | $-28.50 Million |
| Net Cash Flow From Financing Activities | $44.16 Million |
| Net Cash Flow | $-14.47 Million |
| Net Cash Flow, Continuing | $-14.47 Million |
| Net Cash Flow From Investing Activities | $-30.13 Million |
| Net Cash Flow From Investing Activities, Continuing | $-30.13 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Cost Of Revenue | $111.05 Million |
| Income/Loss From Continuing Operations Before Tax | $-52.63 Million |
| Income/Loss From Continuing Operations After Tax | $-52.29 Million |
| Net Income/Loss Available To Common Stockholders, Basic | $-52.29 Million |
| Income Tax Expense/Benefit, Current | $241,000 |
| Net Income/Loss | $-52.29 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss | $-51.88 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss | $405,000 |
| Comprehensive Income/Loss Attributable To Parent | $-51.88 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Liabilities And Equity | $419.38 Million |
| Current Assets | $197.97 Million |
| Noncurrent Liabilities | $119.32 Million |
| Accounts Payable | $7.95 Million |
| Liabilities | $174.13 Million |
| Current Liabilities | $54.82 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||